Cleveland Biolabs (CBLI) Stock News

Possibly Groundbreaking Studies to Be Conducted on the Effectiveness of Short and Long-term COVID-19 Therapies Inhibiting the Progression of SARS-CoV-2

Image by Bruno /Germany via Pixabay  The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a...

Mentions: AMZN CVS WBA STAB

What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?

Statera Biopharma, Inc. (NASDAQ: STAB) — the company formerly known as Cytocom (NASDAQ: CBLI) — recently uplisted to the Nasdaq in lieu of earlier acquisitions...

Mentions: STAB

Cytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc."

New Corporate Name and Updated Stock Ticker Symbol to Showcase Company's Post-Merger Transformation and Focus on Restoring Immune Health

Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast

FORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immu...

Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast

Audio archive for the event may be accessed from the "Investors" section of the Cytocom website

The CMO of Cleveland Biolabs (NASDAQ: CBLI) is Buying Shares

Cytocom, Inc. Reports Second Quarter 2021 Financial Results

-All-stock merger transaction between legacy Cleveland BioLabs and legacy Cytocom recently completed; Cytocom, Inc. common stock trading on Nasdaq as "CBLI"-

Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement

Cytocom to fund research in cancer, autoimmune and inflammatory conditions, and infectious diseases and applications to clinical-stage therapies

Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference

Mike K. Handley, President and CEO, will participate as featured panelist

Cytocom, Inc. to Report Second Quarter 2021 Financial Results

FORT COLLINS, Colo., Aug. 10, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immu...

Cytocom, Inc. to Report Second Quarter 2021 Financial Results

Executive Management to Host Conference Call on Monday, August 16th at 8:30 a.m. ET

Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19

Patient enrollment in Phase 3 pediatric Crohn's disease trial expected to initiate by year-end 2021; End-of-Phase 2 meeting successfully completed in July

Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs

Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing

Financing Led by GEM Global Yield LLC SCS, and Joined by Avenue Capital, and Adit Ventures

Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger

Special Investor Call will be held Wednesday, July 7, at 8:30 a.m. ET

Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC

Special Stockholders Meeting Scheduled for July 6, 2021 to Vote on Proposed Merger Merger Expected to Close During Third Quarter of 2021

Genome Protection Announces Publication of the Next Generation Deimmunized TLR5 Agonist, GP532

The substantially improved pharmacological profile of GP532 opens new opportunities for broader therapeutic applications of this class of pharmaceuticals BUFFALO, NY / ACCESSWIRE / April 14, 2021 / Genome Protection, Inc. (GPI), a joint venture between Cleveland BioLabs, Inc. (NASDAQ:CBLI) and Everon BioSciences, LLC, an innovative biopharmaceutical company focused on developing medical interventions to prevent and treat aging and